One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like 10X Genomics Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell 10X Genomics Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding 10X Genomics Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About 10X Genomics Inc (TXG)

Before we jump into 10X Genomics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

10x Genomics, Inc. is a life science technology company. The Company's integrated platform solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio comprises over 1,750 issued patents and patent applications.

Want to learn more about 10X Genomics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about 10X Genomics Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

10X Genomics Inc’s Stock Price as of Market Close

As of March 31, 2023, 4:00 PM CST, 10X Genomics Inc’s stock price was $55.79.

10X Genomics Inc is up 7.19% from its previous closing price of $52.05.

During the last market session, 10X Genomics Inc’s stock traded between $51.10 and $52.37. Currently, there are 114.77 million shares of 10X Genomics Inc stock available for purchase.

Unfortunately, 10X Genomics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

10X Genomics Inc Stock Price History

10X Genomics Inc’s (TXG) price is currently up 17.4% so far this month.

During the month of March, 10X Genomics Inc’s stock price has reached a high of $56.22 and a low of $43.25.

Over the last year, 10X Genomics Inc has hit prices as high as $83.34 and as low as $23.81. Year to date, 10X Genomics Inc’s stock is down 62.55%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused 10X Genomics Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 30, 2023, there were 5 analysts who downgraded 10X Genomics Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate 10X Genomics Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

10X Genomics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about 10X Genomics Inc (TXG) by visiting AAII Stock Evaluator.

Relative Price Strength of 10X Genomics Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of March 30, 2023, 10X Genomics Inc has a weighted four-quarter relative price strength of 5.66%, which translates to a Momentum Score of 79 and is considered to be Strong.

Want to learn more about how 10X Genomics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

10X Genomics Inc Stock Price: Bottom Line

As of March 31, 2023, 10X Genomics Inc’s stock price is $55.79, which is up 7.19% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell 10X Genomics Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.